Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDKN1A | P38936 | 1/20 | 0.79 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.45 |
| ▸ | BRAF | P15056 | 13/20 | 0.44 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071244 | 0.94 | CDKN1A (0.69) | CDKN1APTPN2PTPN1PTPN6BRAF | |
| SCHEMBL5800545 | 0.90 | CDKN1A (0.66) | CDKN1ABRAFMAPK13PIM1 | |
| SCHEMBL5814680 | 0.90 | CDKN1A (0.86) | CDKN1APTPN1BRAFMAPK13PIM1 | |
| SCHEMBL5808313 | 0.89 | CDKN1A (0.88) | CDKN1ABRAFMAPK13PIM1PABPC1 | |
| SCHEMBL5823272 | 0.89 | CDKN1A (1.00) | CDKN1ABRAFMAPK13PIM1NPC1 | |
| SCHEMBL5820313 | 0.87 | CDKN1A (0.93) | CDKN1ABRAFMAPK13PIM1RAB9A | |
| SCHEMBL5822354 | 0.87 | CDKN1A (0.93) | CDKN1ABRAFMAPK13PIM1RAB9A | |
| SCHEMBL5821207 | 0.86 | CDKN1A (0.92) | CDKN1ABRAFMAPK13PIM1RAB9A | |
| SCHEMBL5808580 | 0.86 | CDKN1A (0.92) | CDKN1ABRAFMAPK13PIM1 | |
| SCHEMBL5823635 | 0.84 | CDKN1A (0.57) | CDKN1ABRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006033795-A2 | SUBSTITUTED PYRAZOLO [1, 5-A] PYRIMIDINES FOR INHIBITING ABNORMAL CELL GROWTH | WYETH (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | WYETH | 2006-03-23 | — | — | US | disclosed |
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | WYETH | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063785-A1 | Substituted pyrazolo[1,5-a] pyrimidines and process for making same | TYMP, DPYD, TYMS | CDKN1A 28/4885PTPN2 1593/4885PTPN1 1017/4885 |
| US-20060063784-A1 | Method of using substituted pyrazolo [1,5-a] pyrimidines | TYMP, DPYD, TYMS | CDKN1A 89/4885PTPN2 1774/4885PTPN1 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.